Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 4/2011

Open Access 01-12-2011 | Prevention of Heart Failure after Myocardial Infarction (Martin St John Sutton, Section editor)

Impact of Diabetes on Postinfarction Heart Failure and Left Ventricular Remodeling

Authors: Helene von Bibra, Martin St John Sutton

Published in: Current Heart Failure Reports | Issue 4/2011

Login to get access

Abstract

Diabetes mellitus, the metabolic syndrome, and the underlying insulin resistance are increasingly associated with diastolic dysfunction and reduced stress tolerance. The poor prognosis associated with heart failure in patients with diabetes after myocardial infarction is likely attributable to many factors, important among which is the metabolic impact from insulin resistance and hyperglycemia on the regulation of microvascular perfusion and energy generation in the cardiac myocyte. This review summarizes epidemiologic, pathophysiologic, diagnostic, and therapeutic data related to diabetes and heart failure in acute myocardial infarction and discusses novel perceptions and strategies that hold promise for the future and deserve further investigation.
Literature
1.
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.PubMedCrossRef
2.
Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294:334–41.PubMedCrossRef
3.
From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119:591–9.PubMedCrossRef
4.
Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community—appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.PubMedCrossRef
5.
•• Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis and treatment. Eur Heart J. 2011;32:670–9. This thorough review considers the complex pathophysiologic and morphologic alterations in the myocardium for diastolic action and dysfunction along with diagnostic algorithms, combined with a discussion of the need for their evaluation. PubMedCrossRef
6.
Malmberg K, Rydén L, Hamsten A, et al. Effects of insulin treatment on cause-specific 1-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMY Study Group. Diabetes insulin-glucose in acute myocardial infarction. Eur Heart J. 1996;17:1337–44.PubMed
7.
Solomon SD, St John Sutton M, Lamas G, et al. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation. 2002;106:1251–5.PubMedCrossRef
8.
Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res. 2009;81:519–27.PubMedCrossRef
9.
Peterson LR, Herrero P, McGill J, et al. Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes. Diabetes. 2008;57:32–40.PubMedCrossRef
10.
How OJ, Aasum E, Severson EL, et al. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes. 2006;55:466–73.PubMedCrossRef
11.
Hansen A, Johansson BL, Wahren J, et al. Beneficial effects of C-peptide on myocardial function and perfusion in patients with type 1 diabetes. Diabetes. 2002;51:3077–82.PubMedCrossRef
12.
von Bibra H, Thrainsdottir IS, Hansen A, et al. Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus: a methodological study. Diabetes Vasc Dis Res. 2005;2:483–7.
13.
Dounis V, Siegmund T, Jensen J, et al. Global myocardial perfusion and diastolic function are impaired to a similar extent in patients with type 2 diabetes mellitus and in patients with CAD—evaluation by contrast echocardiography and pulsed tissue Doppler. Diabetologia. 2006;49:2729–40.PubMedCrossRef
14.
Antonini-Canterin F, Carerj S, Di Bello V, et al. Arterial stiffnes and ventricular stiffness: a couple of diseases or a coupling disease? A review from the cardiologist’s point of view. Eur J Echocardiogr. 2009;10:36–43.PubMedCrossRef
15.
Scuteri A, Najjar SS, Muller DC, et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol. 2004;43:1388–95.PubMedCrossRef
16.
Prasad A, Stone GW, Stuckey TD, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol. 2005;45:508–14.PubMedCrossRef
17.
Kaul S. Myocardial contrast echocardiography—a 25-year retrospective. Circulation. 2008;118:291–308.PubMedCrossRef
18.
Porter TR, Xie F. Myocardial perfusion imaging with contrast ultrasound. J Am Coll Cardiol Cardiovasc Imaging. 2010;3:176–87.
19.
Anderson RA, Evans ML, Ellis GR, et al. The relationship between post-prandial lipemia, endothelial function and oxidative stres in healthy individuals and patients with type 2 diabetes. Atherosclerosis. 2001;154:475–83.PubMedCrossRef
20.
Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long term simvastatin treatment. Circulation. 2002;106:1211–8.PubMedCrossRef
21.
Scognamiglio R, Negut C, De Kreutzenberg SV, et al. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation. 2005;112:179–84.PubMedCrossRef
22.
von Bibra H, Hansen A, Dounis V, et al. Insulin based improved metabolic control augments myocardial diastolic function and perfusion in patients with type 2 diabetes mellitus. Heart. 2004;90:1483–4.CrossRef
23.
Scognamiglio R, Negut C, De Kreutzenberg S, et al. Effects of different insulin regimens on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care. 2006;29:95–100.PubMedCrossRef
24.
Coretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of flow-mediated vasodilatation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–65.CrossRef
25.
Carabba N, Valenti R, Parodi G, et al. Left ventricular remodeling and heart failure in diabetic patients treated with primary angioplasty for acute myocardial infarction. Circulation. 2004;110:1974–9.CrossRef
26.
Fang ZY. Diabetic cardiomyopathy: evidence, mechanisms and therapeutic implications. Endocr Rev. 2004;25:543–67.PubMedCrossRef
27.
•• von Bibra H, St John Sutton M. Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia 2010;53:1033–45. This review considers the complex pathophysiologic pathways linking the metabolic diseases, diabetes mellitus, or the metabolic syndrome to diastolic function and highlights the potential and limitations of the present noninvasive imaging techniques to measure diastolic function and dysfunction. CrossRef
28.
• van Heerebeek L, Hamdani N, Handoko L, et al. Diastolic stiffness of the failing heart: importance of fibrosis, advanced glycation endproducts and myocyte resting tension. Circulation 2008;117:43–51. This is an elegant study using endocardial biopsy specimen of systolic and diastolic heart failure in patients with diabetes. Matrix alterations with fibrosis and/or advanced glycation end products characterize systolic heart failure, whereas diastolic heart failure is associated with increased resting tension. PubMedCrossRef
29.
Serizawa T, Vogel WM, Apstein CS, et al. Comparison of acute alterations in left ventricular relaxation and diastolic chamber stiffness induced by hypoxia and ischemia. J Clin Invest. 1980;68:91–102.CrossRef
30.
Boudina S, Abel ED. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology. 2006;21:250–8.PubMedCrossRef
31.
Kenchaiah S, Sesso HD, Levy D, et al. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation. 2009;119:44–52.PubMedCrossRef
32.
33.
•• Falk Peterson K, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. PNAS 2007;104:12587–94. This is a creative study linking myocellular metabolism of skeletal muscle with hepatic metabolic action in healthy but sedentary individuals with insulin resistance in whom postmeal glycogen synthesis in skeletal muscle is reduced and shifted to hepatic de novo triglyceride generation. CrossRef
34.
McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus—a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170–5.PubMedCrossRef
35.
Rijzewjik LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793–9.CrossRef
36.
Sinnaeve PR, Steg PG, Fox KA, et al. Association of elevated fasting glucose with increased short term and 6 month mortaliy in ST-segment elevation and non ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med. 2009;169:402–9.PubMedCrossRef
37.
Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668–73.PubMed
38.
•• Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy. J Am Coll Cardiol. 2008;51:93–102. This review considers the complex pathophysiologic pathways linking insulin-resistance metabolism and disturbed myocardial function and discusses therapeutic options. PubMedCrossRef
39.
Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes. I. General concepts. Circulation. 2002;105:1727–33.PubMedCrossRef
40.
Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilatation in humans. Circulation. 1998;97:1695–701.PubMed
41.
Roden M. How free fatty acids inhibit glucose utilization in human skeletal muscle. News Physiol Sci. 2004;19:92–6.PubMed
42.
Mathews DR, Hosker JP, Rudensky AS, et al. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRef
43.
Haffner SM, Gonzales C, Mykkänen L, et al. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to type 2 diabetes. Diabetologia. 1997;40:830–7.PubMedCrossRef
44.
Pfützner A, Kunt T, Mondok A, et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Clin Lab. 2004;50:567–73.PubMed
45.
Hohberg C, Pfützner A, Forst T, et al. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual ß-cell function: results from the PioSwitch Study. Diabetes Obes Metab. 2009;11:464–71.PubMedCrossRef
46.
•• Pfützner A, Forst T. Elevated intact proinsulin levels are indicative of beta-cell dysfunction, insulin resistance and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol. 2011;5:784–93. This comprehensive review introduces a scheme to stage type 2 diabetes according to the presence of intact proinsulin, a precursor of insulin, in relation to insulin. PubMed
47.
Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–7.PubMedCrossRef
48.
Yip G, Wang M, Zhang Y, et al. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart. 2002;87:121–5.PubMedCrossRef
49.
Kasner M, Westermann D, Steendijk P, et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction – a comparative Doppler-conductance catheterization study. Circulation. 2007;116:637–47.PubMedCrossRef
50.
Paulus WJ, Tschöpe C, Rusconi C, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–50.PubMedCrossRef
51.
Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107–33.PubMedCrossRef
52.
Wijns W, Serruys PW, Slager C, et al. Effect of coronary occlusion during percutaneous transluminal angioplasty in humans on left ventricular chamber stiffness and regional diastolic pressure-radius relations. J Am Coll Cardiol. 1986;7:455–63.PubMedCrossRef
53.
Charlat ML, O’Neill PG, Hartley CJ, et al. Prolonged abnormalities of left ventricular diastolic wall thinning in the “stunned” myocardium in conscious dogs: time course and relation to systolic function. J Am Coll Cardiol. 1989;13:185–94.PubMedCrossRef
54.
von Bibra H, Tuchnitz A, Klein A, et al. Regional diastolic function by pulsed Doppler myocardial mapping for the detection of left ventricular ischaemia during pharmacologic stress testing—a comparison with stress echocardiography and perfusion scintigraphy. J Am Coll Cardiol. 2000;36:444–52.CrossRef
55.
Bess RL, Rosman HS, Cohen GI, et al. Technical aspects of diastology: why mitral inflow and tissue Doppler imaging are the preferred parameters? Echocardiography. 2006;23:332–9.PubMedCrossRef
56.
Mulvagh S, Rakowski H, Vannan MA, et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr. 2008;21:1179–201.PubMedCrossRef
57.
Senior R, Becher H, Monaghan M, et al. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography. Eur J Echocardiogr. 2009;10:194–212.PubMedCrossRef
58.
•• Villanueva FS. Myocardial perfusion imaging using ultrasound contrast agents – now or never? J Am Coll Cardiol Cardiovascular Imaging 2010;3:944–6. This is a knowledgeable consideration of the potential of myocardial contrast echocardiography, its clinical value, and the potential reasons for the delay in acceptance by clinicians.
59.
Gropler RJ, Beanlands RS, Dilsizian V, et al. Imaging myocardial metabolic remodeling. J Nucl Med. 2010;51:88–101.CrossRef
60.
American Diabetes Association. Nutrition recommendations and interventions for diabetes. Diabetes Care. 2008;31 Suppl 1:61–78.CrossRef
61.
Mann JI, Hermansen K, Karamanos B, on behalf of the Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD), et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis. 2004;14:373–94.PubMedCrossRef
62.
•• Marantz PR, Bird ED, Alderman MH. A call for higher standards of evidence for dietary guidelines. Am J Prev Med. 2008;34:234–40. This is a 30-year observation on fat intake, carbohydrate consumption, and body weight development in American men and women, leading to the insight that dietary guidelines need higher standards of evidence to avoid damage on a population level. PubMedCrossRef
63.
Yusuf S, Hawken S, Ounpuu S, on behalf of the INTERHEART Study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.PubMedCrossRef
64.
•• Accurso A, Bernstein RK, Dahlqvist A, et al. Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab. 2008;5:9–17. This sound and basic review focuses on physiologic mechanisms working in diabetes metabolism and critically discusses the respective nutritional recommendations and pharmacological treatments.CrossRef
65.
• Buyken AE, Mitchell P, Ceriello A, et al. Optimal dietary approaches for prevention of type 2 diabetes: a life-course perspective. Diabetologia 2010;53:406–18. This thorough review considers the complex pathophysiologic and metabolic alterations in type 2 diabetes potentially leading to heart failure, along with diagnostic algorithms and a thorough discussion about the large field of literature on antidiabetic treatment. PubMedCrossRef
66.
Elhayany A, Lustman A, Abel R, et al. A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. Diabetes Obes Metab. 2010;12:204–9.PubMedCrossRef
67.
Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low carb, Mediterranean, or low fat diet. New Engl J Med. 2008;359:229–41.PubMedCrossRef
68.
Rallidis LS, Lekakis J, Kolomvotsou A, et al. Close adherence to a Mediterranean diet improves endothelial function in subjects with abdominal obesity. Am J Clin Nutr. 2009;90:263–8.PubMedCrossRef
69.
Volek JS, Ballard KD, Silvestre R, et al. Effects of dietary carbohydrate restriction vs low-fat diet on flow mediated dilatation. Metab Clin Exp. 2009;58:1769–77.PubMedCrossRef
70.
von Bibra H, Wulf G, Schumm-Draeger PM, et al. Cardiac function and insulin resistance improved by a low-glycemic/high-protein diet but not by low-fat diet in overweight type 2 diabetes patients abstract. Diabetes. 2010;59 suppl 1:A124.
71.
Hammer S, Snel M, Lamb HJ, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol. 2008;52:1006–12.PubMedCrossRef
72.
Rider OJ, Francis JM, Ali MK, et al. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. J Am Coll Cardiol. 2009;54:718–26.PubMedCrossRef
73.
Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk—results from the PREMIER trial. Circulation. 2009;119:2026–31.PubMedCrossRef
74.
Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–51.PubMedCrossRef
75.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.CrossRef
76.
Anderson C, Sogaard P, Hoffmann S, et al. Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes. Eur J Endocrinol. 2010;163:593–9.CrossRef
77.
78.
Eurich DT, McAlicster FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007;335:497–507.PubMedCrossRef
79.
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. October 7, 2003. Circulation. 2003;108:2941–8.PubMedCrossRef
80.
Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of EnaC-mediated renal salt absorption. Nat Med. 2005;11:861–6.PubMedCrossRef
81.
van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119:2069–77.PubMedCrossRef
82.
Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with the New York Heart Association functional class I—II heart failure. J Am Coll Cardiol. 2007;49:1696–704.PubMedCrossRef
83.
Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583–90.PubMedCrossRef
84.
Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Health Care Project. Diabetes Care. 2005;28:1680–9.PubMedCrossRef
85.
Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like pepetide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209–15.PubMedCrossRef
86.
Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007;293:E1289–95.PubMedCrossRef
87.
Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–5.PubMedCrossRef
88.
Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824–9.PubMedCrossRef
89.
Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694–9.PubMedCrossRef
90.
Bunck MC, Cornér A, Eliasson B, et al. One year treatment with exenatide vs insulin glargine: effects on postprandial glycemia, lipid profiles and oxidative stress. Atherosclerosis. 2010;212:223–9.PubMedCrossRef
91.
Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010;212:217–22.PubMedCrossRef
92.
Koska J, Schwartz E, Mullin MP, et al. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care. 2010;33:1028–30.PubMedCrossRef
93.
Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with CAD. Circ Cardiovasc Imaging. 2010;3:195–201.PubMedCrossRef
94.
•• De Caterina R, Madonna R, Sourij H, et al. Glycemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J. 2010;31:1557–64. This review discusses the large amount of pharmaceutical studies that attempted to improve patient’s outcome via normalization of hyperglycemia and resulted in inconclusive findings. PubMedCrossRef
95.
Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes committee of the Council of Nutrition, Physical Activity and Metabolism. Circulation. 2008;117:1610–9.PubMedCrossRef
96.
Van de Werf F, Bax J, Betrui A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909–45.PubMedCrossRef
97.
Hochmann JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006;355:2395–407.CrossRef
98.
Appleton DL, Abbate A, Biondi-Zoccai GG, et al. Late percutaneous coronary intervention for the totally occluded infarct-related artery: a meta-analysis of the effects of cardiac function and remodeling. Catheter Cardiovasc Interv. 2008;71:772–81.PubMedCrossRef
99.
Funaro S, La Torre G, Madonna M, et al. Incidence, determinants and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study. Eur Heart J. 2009;30:566–75.PubMedCrossRef
100.
Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003;41:1–7.PubMedCrossRef
Metadata
Title
Impact of Diabetes on Postinfarction Heart Failure and Left Ventricular Remodeling
Authors
Helene von Bibra
Martin St John Sutton
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current Heart Failure Reports / Issue 4/2011
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-011-0070-8

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits